Additionally, encapsulation procedures for chemotherapeutic agents, that is, doxorubicin and paclitaxel, have been established. These unique alternating copolymer micelle nanoparticles were designed as delivery vehicles targeted to human

cancer cells expressing the underglycosylated mucin-1 antigen, which is found on almost all epithelial cell adenocarcinomas, by use of the peptide EPPT, or the folate receptor (FR) by using folate. Development Inhibitors,research,lifescience,medical of the synthetic schemes has been coupled with in vitro toxicity tests using various cell viability assays to minimize the toxic effect of these copolymer structures. The nontoxic polymers were brought forward Inhibitors,research,lifescience,medical into drug delivery and uptake experiments. Cell death due to doxorubicin increased with encapsulation

in these alternating copolymers. Additional slight improvements were observed when targeting ligands were attached to the encapsulating polymer. Similar results were obtained with paclitaxel as the cargo. Cellular uptake determined by 125I or 3H radioactive analysis and fluorescence confocal microscopy was also investigated in other in vitro studies. Microscopy images of the labeled polymer alone selleck chemicals demonstrated that the polymer was most likely confined to vesicles within the cytoplasm and not found in the nucleus, whereas encapsulated Inhibitors,research,lifescience,medical doxorubicin was shown to be largely confined to the nucleus. Theoretical models of polyvalent binding were employed Inhibitors,research,lifescience,medical to guide the design of the targeting polymers. Unfortunately, the polymers used in this study appeared largely nonspecific for the targeted cells when studied in vitro. However, the versatility of these polymer constructs suggests that continuing to optimize for a targeting delivery Inhibitors,research,lifescience,medical system for drugs and imaging agents using this polymer platform could be extremely beneficial. 2.2.3. Attachment to T-cell Surfaces Before discussing the specifics of the use of T-cells in drug delivery protocols, a few general comments about the underlying Non-specific serine/threonine protein kinase principles are appropriate. The basis of this approach

is attributed to the new, burgeoning field of biohybrid materials which will have a significant impact on the efficacy of drug delivery. This is in addition to their obvious use in bioimaging, cellular functionalization, immune system and tissue engineering, and cell-based therapeutics where cell-environment interactions are critical. Of particular interest here are synthetic materials systems such as magnetic micromanipulators, nanoparticulate cellular patches, and functional cell backpacks [31, 32]. These offer exciting possibilities for symbiosis between synthetic building blocks and native biological behavior. The key is the ability to systematically modify the surface of living cells.